For me it is a perfect forum to understand market dynamics in clinical supply chain management such as accelerated drug developments, GDP/GMP annex 15 risk management, and innovative supply chain solutions.
I have always brought back something useful to my working life from every ISPE conference I have ever attended. Often enough, I made long-standing business relationships and got input, especially about cutting-edge digital innovations, such as IVRS in the early developmental days or electronic labels nowadays.
Most importantly, as the Co-Chair of the Steering Committee for the ISPE Europe Community of Practice for Investigational Products, I am excited to attend sessions under Track 3: Clinical and ATMP Supply Chain. Here are a few track highlights:
April 4th – Accelerated Development – Afternoon Session The industry and regulatory speakers will touch on trends and potential solutions, including faster selection of drug candidates and clinical trials with Advanced Therapy Medicinal Products (ATMP).
April 5th – GDP & GMP Annex 15 Risk Management – Morning Session You will get brand new regulatory updates and hear various case studies. One focus will be on Direct-to-Patient supplies. Share and learn more in a planned risk based distribution workshop.
April 5th – Patient Centricity & Innovative Supply Chain Approaches – Afternoon Session Listen to patient representatives, clinical supply chain and technology experts and discuss how value can be created for patients in clinical trials.
I’m looking forward to this unique opportunity to enhance my technical knowledge, exchange ideas with my peers, and gain insight from industry experts. I’m looking forward to seeing you at the 2017 ISPE Europe Annual Conference! By: Jens Mattuschka World Courier, an AmerisourceBergen company RVP | Nordics, Central and Eastern Europe
Are you considering joining ISPE? Or maybe you’ve recently joined the society or are a longtime member looking to better understand all the benefits available to you. If so, you’ve come to the right place!
ATMPs are based on genes, cells or tissues delivered to patients to provide a therapeutic benefit based on a specific target of interest. Often referred to as ‘Personalised Medicine’. A sector of healthcare that is rapidly evolving and expanding with some unique challenges such as microbial contamination and product variability. Traditional manufacturing processes are for synthetically derived...
GAMP® 5 Second Edition is here! Since its publication, GAMP® 5 has been far and away the leading international guidance on GxP computerized systems validation and compliance, and it was time to update our guidance to...